Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago CAR-T

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

AACR2024

#AACR2024

At the 2024 American Association for Cancer Research (#AACR) Annual Meeting, innovative drugs from China showed promising safety and preliminary efficacy in early clinical trials, attracting high interest from attending experts and researchers, showcasing the strength of #Chineseresearch teams in new drug development.

#TQB2916

A groundbreaking focus of cancer research is on #TQB2916, the latest #CD40 agonist antibody causing a stir in the medical field.

#CD40

receptors, a member of the tumor necrosis factor receptor family, play a vital role in immune responses. TQB2916, a humanized IgG2 CD40 monoclonal antibody, has demonstrated CD40 activation and promising anti-tumor activity in preclinical studies. With its potential to revolutionize cancer treatment, TQB2916 is currently undergoing its first human study for late-stage solid tumors and lymphomas, led by the team at Tianjin Medical University Cancer Institute & Hospital.

#ECOG

Now, let’s delve into the details: Eligible patients, including those with an ECOG performance status of 0 or 1, adequate hematologic and organ function, and no response to standard treatments, are enrolled. TQB2916 is administered intravenously every 3 weeks until disease progression or unacceptable toxicity. The study utilizes a Bayesian Optimal Interval (BOIN) design to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TQB2916.

#Realcase

From April 2022 to November 2023, a total of 18 patients with solid tumors and 2 with lymphomas underwent TQB2916 monotherapy and were assigned to 7 dose cohorts. Adverse events were observed, with the most common including lipase increase, amylase increase, lymphocyte count decrease, ALT increase, ALP elevation, AST elevation, hypoalbuminemia, and anorexia. However, most adverse events were manageable, primarily Grade 1 or 2 severity.

#Lymphomas

Of the 16 evaluated patients, 3 achieved stable disease according to immune RECIST criteria for solid tumors and LYRIC criteria for lymphomas. Pharmacokinetic analyses showed favorable performance, with no drug accumulation upon repeat dosing. Additionally, dose-dependent occupancy of CD40 receptors was detected, alongside peripheral B cell reduction and increased cytokine secretion.

#Conclusion

TQB2916 achieves CD40 engagement and immune activation through cytokine modulation. With its promising safety and efficacy profile, 200mg has been identified as the preliminary expansion dose. Studies exploring TQB2916 in combination with immune checkpoint inhibitors and/or other anti-cancer therapies are currently underway.

Stay tuned for more updates on this groundbreaking treatment!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com

WhatsApp +86137 1795 9070

The Medical Department will contact you as soon as they receive the reports.

#CancerResearch #Immunotherapy #MedicalBreakthrough #AACR22024 #chinesemedical

8 months ago CAR-T

AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team

AACR 2024

We’re thrilled to share groundbreaking updates from the 2024 American Association for Cancer Research (AACR) Annual Meeting!

China’s innovative pharmaceuticals are making waves in early clinical trials, hinting at promising breakthroughs in cancer treatment!

At the forefront is the remarkable research on Treprilimumab, a monoclonal antibody, showcased by Prof. Ma Haiqiang and his team from Sun Yat-sen University Cancer Center.

Their pioneering work focuses on advancing treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a challenging form of cancer.

Treprilimumab, administered subcutaneously, has shown remarkable safety and preliminary efficacy when combined with Gemcitabine and Cisplatin (GP), earning FDA approval in October 2023 for first-line therapy in RM-NPC.

The team initiated the first human clinical trial to assess Treprilimumab’s pharmacokinetics in RM-NPC, aiming to establish optimal subcutaneous dosing regimens for future trials.

The study enrolled RM-NPC patients, confirmed histologically, and previously untreated systemically. Patients received Treprilimumab SC at 240mg Q3W, 360mg Q3W, or 480mg Q6W, in combination with GP for up to 6 cycles, followed by Treprilimumab SC monotherapy until disease progression, intolerable toxicity, or completion of 2 years of treatment. Tumor response was assessed by RECISTv1.1 criteria, with primary endpoints focusing on pharmacokinetics and secondary endpoints including safety, efficacy, and immunogenicity.

From November 24, 2022, to November 20, 2023, 38 patients were enrolled, with a median follow-up of 6.8 months. The median age was 49, with 73.7% male. Pharmacokinetic analysis revealed comparable exposure between Treprilimumab 360mg Q3W SC and 240mg Q3W IV in the first cycle. Overall response rates (ORR) were 100%, 92.3%, and 92.3% for the 240mg, 360mg, and 480mg groups, respectively. By November 20, 2023, 71.1% of patients experienced sustained remission, with no new safety concerns. Grade ≥3 adverse events (AEs) occurred in 76.3% of patients, with no fatalities. Immune-related AEs were reported in 36.8% of patients, with one case of grade ≥3.

These groundbreaking findings demonstrate comparable safety and clinical efficacy between Treprilimumab SC and IV formulations when combined with GP in treating RM-NPC patients. The exposure of Treprilimumab 360mg Q3W SC mirrors that of 240mg Q3W IV. Excitingly, Treprilimumab SC formulations are slated for Phase III clinical development, promising hope for enhanced cancer therapies!

Stay tuned for more updates on this game-changing research!

To assess whether the condition is suitable for Chinese Top level therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#AACR2024 #CancerResearch #InnovationInMedicine

Menu

Tags Archives: AACR 2024

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas

#AACR2024

#TQB2916

#CD40

#ECOG

#Realcase

#Lymphomas

#Conclusion

Stay tuned for more updates on this groundbreaking treatment!

doctor.huang@globecancer.com

WhatsApp +86137 1795 9070

#CancerResearch #Immunotherapy #MedicalBreakthrough #AACR22024 #chinesemedical

AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team

AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team

We’re thrilled to share groundbreaking updates from the 2024 American Association for Cancer Research (AACR) Annual Meeting!

China’s innovative pharmaceuticals are making waves in early clinical trials, hinting at promising breakthroughs in cancer treatment!

At the forefront is the remarkable research on Treprilimumab, a monoclonal antibody, showcased by Prof. Ma Haiqiang and his team from Sun Yat-sen University Cancer Center.

Their pioneering work focuses on advancing treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a challenging form of cancer.

Treprilimumab, administered subcutaneously, has shown remarkable safety and preliminary efficacy when combined with Gemcitabine and Cisplatin (GP), earning FDA approval in October 2023 for first-line therapy in RM-NPC.

The team initiated the first human clinical trial to assess Treprilimumab’s pharmacokinetics in RM-NPC, aiming to establish optimal subcutaneous dosing regimens for future trials.

Stay tuned for more updates on this game-changing research!

To assess whether the condition is suitable for Chinese Top level therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

Recent Posts